Evidence map›Paper›PMID 37080728›Full record

Observational studyEpidemiology and health2023

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.

Hong Ki Min, Hyeongsu Kim, Ho Jin Jeong, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee, KunSei Lee, Soon-Ae Shin, Jong Heon Park

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Epidemiology and health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hong Ki MinDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
Hyeongsu KimDepartment of Preventive Medicine, Konkuk University School of Medicine, Seoul, Korea.
Ho Jin JeongDepartment of Preventive Medicine, Konkuk University School of Medicine, Seoul, Korea.
Se Hee KimDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
Hae-Rim KimDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
Sang-Heon LeeDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
KunSei LeeDepartment of Preventive Medicine, Konkuk University School of Medicine, Seoul, Korea.
Soon-Ae ShinBig Data Strategy Department, National Health Insurance Service, Wonju, Korea.
Jong Heon ParkBig Data Strategy Department, National Health Insurance Service, Wonju, Korea.
Konkuk University · KRKonkuk University Medical Center · KRNational Health Insurance Service · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study investigated whether Janus kinase inhibitors (JAKis) raise the risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and cancer in patients with rheumatoid arthritis (RA).

methodsWe conducted a real-world retrospective observational study using data obtained from the Korean National Health Insurance Service database. Two data sets were analyzed: tumor necrosis factor inhibitor (TNFi)/JAKi-naive RA patients (set 1) and all RA patients who used TNFis or JAKis (set 2). The incidence rate ratios (IRRs) and hazard ratios (HRs) for acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), VTE, arterial thromboembolism (ATE), cancer, and all-cause mortality were compared between the JAKi and TNFi groups.

resultsSet 1 included 1,596 RA patients (JAKi group: 645; TNFi group: 951), and set 2 included 11,765 RA patients (JAKi group: 2,498; TNFi group: 9,267). No adverse events (AEs) showed significantly higher IRRs in the JAKi groups than in the TNFi groups of sets 1 and 2. The HRs for MACE in the JAKi groups of sets 1 and 2 were 0.59 (95% confidence [CI], 0.35 to 0.99) and 0.80 (95% CI, 0.67 to 0.97), respectively. The JAKi group of set 2 showed a significantly higher risk of all-cause mortality (HR, 1.71; 95% CI, 1.32 to 2.20), but the other AEs did not demonstrate increased risks in the JAKi groups.

conclusionsIn this study, JAKis did not increase the risk of AMI, stroke, CV-related mortality, MACE, VTE, ATE, or cancer in Korean RA patients relative to TNFis.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCardiovascular DiseasesJanus Kinase InhibitorsMyocardial InfarctionNeoplasmsVenous ThromboembolismHumansInsurance, HealthRepublic of KoreaTumor Necrosis Factor-alphaAntirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor-alphaCancerCardiovascular diseaseJanus kinase inhibitorRheumatoid arthritisTumor necrosis factor inhibitorVenous thromboembolism

Identifiers

PMID37080728
PMCPMC10396807
OpenAlexW4366290662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.